Full-Time

Senior Medical Director

Medical Affairs, Nephrology

Vertex Pharmaceuticals

Vertex Pharmaceuticals

5,001-10,000 employees

Develops therapies for serious genetic diseases

Compensation Overview

$252k - $378k/yr

+ Bonus + Equity Awards

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid

Hybrid role; up to two remote days per week.

Category
Biology & Biotech (2)
,
Required Skills
Google Cloud Platform
Requirements
  • Medical Degree MD or Doctor of Medicine or DO in Nephrology.
  • Typically requires 10 years of experience and 3 years of supervisory/management experience or the equivalent combination of education and experience.
  • Deep understanding of global medical, regulatory and commercial environments.
  • Excellent understanding of government and industry guidelines, regulations, laws, etc., for appropriate scientific/medical exchange and communication with key external stakeholders (e.g., healthcare providers, payers, advocacy bodies).
  • Deep understanding of market access in key countries.
  • Excellent written and oral communication skills to influence others internally/externally.
  • Ability to develop relationships in a highly matrixed environment, as well as external relationships with global, regional and local thought leaders and industry experts.
  • Ability to engage in positive dialogue and resolve conflicts in a constructive manner.
  • Track-record of ability to plan, initiate and complete projects within allotted time frames & delivering high quality successful results.
  • Ability to work within a multi-disciplinary and multi-cultural team on common projects and goals, at national and regional level.
  • Capacity to critically analyze current scientific literature.
Responsibilities
  • Demonstrate consistent ethical and professional behavior, with uncompromising commitment to patients
  • Ensure all medical involvement and activities are executed in full compliance with Vertex policies, local laws and regulations and codes of practice.
  • Continue to build reputation and visibility of Vertex at the regional and country level by providing fair and balanced medical information, communication and education to various stakeholders, supporting research and relevant data generation with the ultimate goal of supporting the safe and effective use of Vertex’ medicines in the appropriate patients
  • Work closely with the designated region medical leadership to ensure a culture of integrity, transparency and respect, as per Vertex values, throughout the organization
  • Align medical strategy with organizational goals by ensuring own and team responsibilities and goals are aligned with the long-term aims of the organization and other departments.
  • Develop and ensure flawless execution, via the medical team, of the designated disease area Medical Strategic and Operational Plan, in accordance with corporate policies and procedures and applicable local laws, regulations and code of practice
  • Provide strategic regional input and participate in the development of Life Cycle Management (LCM) Plans
  • Drive data generation studies/projects to enhance medical-scientific knowledge in the Therapeutic Area(s) and ensure implementation of RWD initiatives and LCM plans in the region, as appropriate
  • Provide feedback on Global Development Programs to ensure local needs are taken into account
  • Accountable for supporting the Regional Medical Leads in the development, implementation and execution of the Regional Medical Strategy and plan for pipeline and in market products
  • Establishes and tracks medical KPIs that demonstrate impact on business and patient outcomes.
  • Uses scenario planning and market foresight to prepare for multiple potential realities, adapting strategies and plans to respond to evolving internal and external environments.
  • Applies structured problem-solving and root cause analysis to identify solutions that maximize medical and business impact
  • Develop and maintain high level, clinical and scientific knowledge in the designated disease area and good knowledge of all Vertex disease areas.
  • Provide strong leadership inspiring and empowering a dedicated medical team and promoting a culture of continuous development.
  • Accountable to recruit, develop, manage and coaches the designated location medical team.
  • Leverages the capabilities and expertise of the team to ensure successful execution of medical plans
  • Identifies and addresses team skill gaps, considering how to accelerate internal talent or attract external to meet needs of a future-ready organization.
  • Ensure formal goal-setting, appraisals, individual development plans (IDPs) take place in a timely and structured manner
  • Ensure excellent working partnerships are developed with Health Care Professionals (HCPs) based on scientific excellence and trust
  • Continue to maintain and establish relationships with External Experts to expand research opportunities
  • Develop and execute at regional and support local level, advisory, collaborative and/or educational activities aligned to the Vertex strategy
  • Contribute to transparent and successful partnerships with national scientific societies, patient organizations, relevant payers, policymakers and relevant industry associations
  • Provide fair and balanced medical information and education to health care professionals and HTA/payer stakeholders that support the safe and effective use of Vertex’ medicines in the appropriate patients
  • Deliver external presentations (advisory board meetings, symposia, other medical education meetings) to enhance the medical knowledge of pipeline and marketed products, as required and in accordance with local regulations and procedures
  • Tailors communications to stakeholder needs, building trust and understanding across diverse audiences.
  • Ensure adequate internal training is provided to medical and XFT, contribute individually as appropriate
  • Ensure compliance of medical activities at country level with country Code of Conduct, rules and regulations, company policies, SOPs, GCP and ICH
  • Assess region/local promotional materials and ensure that all claims are fully supported by scientific data, and are presented in an accurate, fair and balanced manner
  • Ensure self and other regional medical staff have the required skills to identify and report AEs appropriately
  • Contribute to managing external communication when significant safety issues arise, with the wellbeing of patients being the ultimate goal
  • Work in partnership with the Commercial leaders as well as other cross functional team (XFT) colleagues to ensure that the appropriate patients have fair access in a safe and effective manner, support development and implementation of the designated region cross functional plans aligned with patient, HCPs’ and broader corporate needs
  • Ensure high level of support and contribution to access efforts through the preparation/review of reimbursement dossiers, scientific engagement of key stakeholders, presentation of scientific data as required to key stakeholders in the access process
  • Ensure incorporation of medical insights into strategy, perform data gap analysis relevant to access and support locally needed data generation as appropriate
  • Lead accountability for reviewing and certification of promotional and non-promotional materials in the respective area according to the company SOP and to local country and regional regulations
  • Responsible for medical interpretation of data (clinical trials, registries, published literature, etc.) for in-development compounds and marketed medicines for the region
  • Keep product and pipeline information up to date based on internal and external publications
  • Work closely with key internal and external stakeholders, supporting Vertex’ strategy and bringing medical insights as well as support for HTA bodies, media, government and patient group activities, including policy development, corporate initiatives and issues management
  • Maintain a seamless flow of information within and between the local structure and designated region Medical Affairs, and communicate medical insights obtained locally from appropriate field interactions to inform local, regional and global strategy/tactics
  • Strategic alignment working cross functionally and partnering with other key functions at Vertex such as Commercial, Market Access, Health Economics Outcomes Research, Regulatory and Corporate Communications
  • Work in strategic partnership with Regulatory, Pharmacovigilance, Medical Information, Clinical Development, Global Clinical Operations and Health Economics Outcomes Research teams in medical scientific questions
  • Ensure own and team responsibilities and goals are aligned with the long term aims of the organization and other departments
  • Support for issues related to supply and distribution, product quality, benefit-risk, market actions and product withdrawals
  • Considers the downstream impact of medical decisions on countries, other functions, and stakeholders
  • Facilitate appropriate and adequate implementation of compassionate use programs in country
  • Ensure sourcing accurate epidemiology data in collaboration with local registries/other stakeholders, as applicable
  • Ensure medical team supports Investigator Initiated research aligned with strategic areas of interest and in a compliant manner
  • Ensure appropriate Steering Committee meetings and advisory boards are held in accordance with local and company regulations. As appropriate leads such initiatives
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hits $2.96B, up 12% from strong CF demand.
  • Hypercon deal with Halozyme enables at-home subcutaneous delivery.
  • CASGEVY expands to UAE via Yas Clinic on March 31, 2026.

What critics are saying

  • VX-264 diabetes therapy halts after Phase 1/2 C-peptide failure March 28.
  • VX-993 pain drug fails Phase 2 primary endpoint in Q2 2026.
  • CSO Altshuler retires August 2026, leaving 6-month research vacuum.

What makes Vertex Pharmaceuticals unique

  • Vertex dominates cystic fibrosis with Trikafta and ALYFTREK modulators.
  • CASGEVY delivers first CRISPR/Cas9 gene therapy for sickle cell.
  • JOURNAVX pioneers NaV1.8 inhibition for acute pain approval.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Vertex Pharmaceuticals who can refer or advise you

Benefits

Hybrid Work Options

Company News

Investing.com
Apr 13th, 2026
Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026.

Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026. Published 04/13/2026, 06:16 AM (C) Reuters. Investing.com - Bank of America has reaffirmed Argenx (NASDAQ:ARGX) and Vertex Pharmaceuticals (NASDAQ:VRTX) as its top large-cap biotech picks for 2026, with price targets of $1,013 and $598, respectively. For Argenx, BofA cited strong commercial performance of Vvygart in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, driven by expansion into earlier treatment lines and growing real-world experience. The firm highlighted upcoming phase 3 results for efgartigimod in myositis in the third quarter and empasiprubart in multifocal motor neuropathy in the fourth quarter as potential catalysts. For Vertex, BofA emphasized the strength of the cystic fibrosis franchise in providing cash flow to support pipeline expansion. The firm identified the rare kidney disease franchise as a key long-term growth driver, noting positive data for povetacicept in IgA nephropathy. Among commercial small- and mid-cap picks, BofA selected KalVista Pharmaceuticals (NASDAQ:KALV) with a $32 price target and Rhythm Pharmaceuticals (NASDAQ:RYTM) with a $149 price target. KalVista's Ekterly was approved in July 2025 as the first on-demand hereditary angioedema therapy, while Rhythm's Imcivree became the first approved therapy for acquired hypothalamic obesity in March. For pre-commercial small- and mid-cap stocks, BofA named Ocular Therapeutix (NASDAQ:OCUL) with a $27 price target and Bicara Therapeutics (NASDAQ:BCAX) with a $35 price target as top picks. Should you invest $2,000 in VRTX right now? ProPicks AI evaluates VRTX alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias - it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if VRTX is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

National Today
Apr 11th, 2026
Fiduciary Alliance buys $2.2M stake in Vertex Pharmaceuticals

Fiduciary Alliance LLC purchased 4,828 shares of Vertex Pharmaceuticals during the fourth quarter, valued at approximately $2.19 million, according to a recent 13F filing with the Securities and Exchange Commission. The investment reflects confidence in the Boston-based biotechnology company, which specialises in developing treatments for serious diseases, particularly cystic fibrosis. Vertex's portfolio of CFTR modulators has transformed standards of care for many CF patients. Vertex's share price has risen over 20% in the past year as the company continues expanding its cystic fibrosis treatments and exploring new therapeutic areas. The investment signals institutional interest in Vertex's growth potential and drug pipeline.

GlobalData
Apr 8th, 2026
Halozyme and Vertex sign deal for Hypercon technology.

Halozyme and Vertex sign deal for Hypercon technology. Under the agreement, Vertex will make a $15m upfront payment to Halozyme and potential future milestone payments. Halozyme Therapeutics' subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former's Hypercon technology. Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. The Hypercon microparticle platform enables hyperconcentration of drugs and biologics, aiming to reduce injection volume and facilitate at-home administration for patients. Vertex will make an upfront payment of $15m to Halozyme, along with potential future milestone payments. Halozyme will also receive royalties on net sales of any products that are developed using the technology. Halozyme Therapeutics president and CEO Helen Torley said: "This collaboration with Vertex underscores the versatility and potential of its Hypercon technology to enable small volume, patient-delivered next generation biologics. "Vertex is a proven innovator with deep expertise, and we believe Hypercon can play an important role in supporting improved ease of patient access to targeted biologics that have the potential to advance innovation for patients with serious diseases." Halozyme's Enhanze drug delivery technology, based on the enzyme rHuPH20, supports the subcutaneous administration of injected drugs and fluids to lower treatment burden and enhance convenience. Enhanze has been involved in over one million patient lives through ten commercialised products across more than 100 countries, and is licensed to companies such as AbbVie, Eli Lilly, Pfizer, Roche, Takeda, and ViiV Healthcare. Halozyme has expanded its drug delivery portfolio to include Hypercon, as well as Surf Bio's polymer-based hyperconcentration technology, broadening the possibilities for subcutaneous biologics delivery. In January 2026, Takeda announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the latter's Enhanze drug delivery technology. Give your business an edge with its leading industry insights.

The Pharma Letter
Apr 8th, 2026
Halozyme inks license agreement with Vertex.

Halozyme inks license agreement with Vertex. 8 April 2026 San Diego, USA-based Halozyme Therapeutics (Nasdaq: HALO) late yesterday announced it has entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals (Nasdaq: VRTX). This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 17 November 2025 25 April 2025 14 September 2017 Company news directory. Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 8 April 2026 7 April 2026 Company spotlight. A clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases characterized by abnormal appetite and metabolic disorders. More features in pharmaceutical. 8 April 2026 7 April 2026

UAE News.Net
Mar 31st, 2026
Abu Dhabi records major healthcare milestones in Q1 2026, reinforcing global leadership.

Abu Dhabi records major healthcare milestones in Q1 2026, reinforcing global leadership. WAM 31 Mar 2026, 19:06 GMT+ ABU DHABI, 31st March, 2026 (WAM) - The Emirate of Abu Dhabi has achieved a series of significant medical and scientific milestones during the first quarter of 2026, reflecting the rapid advancement of its healthcare ecosystem and reinforcing its position as a regional and global hub for medical innovation and advanced therapies. Supported and overseen by the Department of Health - Abu Dhabi, and in collaboration with leading healthcare institutions and global partners, Yas Clinic Khalifa City, in cooperation with the Abu Dhabi Stem Cells Center and Vertex Pharmaceuticals, successfully administered the UAE's first gene-editing therapy for haemoglobin disorders using "CASGEVY," based on CRISPR/Cas9 technology, marking a groundbreaking national achievement. Sheikh Khalifa Medical City also recorded a medical milestone by performing the UAE's first cardiac biopsy on a paediatric patient following a heart transplant, as part of the visiting physicians programme, further enhancing specialised healthcare services within the country. Cleveland Clinic Abu Dhabi achieved several pioneering procedures, including the UAE's first breast reconstruction surgery using the Deep Inferior Epigastric Perforator (DIEP) flap with robotic assistance for a breast cancer survivor. The hospital also conducted robotic-assisted stereoelectroencephalography (SEEG), representing a major advancement in diagnosing and treating complex epilepsy cases. Additionally, it performed the first remote robotic-assisted nephroureterectomy between the UAE and Pakistan, highlighting significant progress in robotic surgery and expanding access to advanced care. The hospital further carried out the first basivertebral nerve ablation using the "Intracept" procedure in the Middle East and North Africa, marking a notable development in pain management. PureLab, a subsidiary of PureHealth Group, in collaboration with LOD Autonomous, launched a pilot project to transport blood samples via drones between Sheikh Khalifa Medical City and its Abu Dhabi facility, enhancing laboratory efficiency and accelerating sample delivery. Burjeel Medical City inaugurated the Burjeel Eye Institute, managed by Emirati professionals, alongside the launch of the Advanced Sarcoma and Bone Tumour Centre in collaboration with Burjeel Orthopaedic Institute. In a significant scientific breakthrough, the group also announced the discovery of a previously undocumented rare genetic disorder, "El-Hattab-Schmidts syndrome," affecting brain development and muscle strength, opening new avenues for innovative gene therapies for children. The city also launched the Abu Dhabi Neuro-Oncology Centre, in collaboration with Burjeel Cancer Institute and the Neuroscience Institute, to provide comprehensive and advanced care for patients across all age groups. Sheikh Shakhbout Medical City introduced an advanced treatment option involving implantable hypoglossal nerve stimulation for obstructive sleep apnoea in adults, improving patients' quality of life. The hospital also adopted video-assisted thoracoscopic surgery (VATS), including uniportal sympathectomy, performed through a small concealed incision, reducing pain, accelerating recovery, and improving cosmetic outcomes. The Department of Health - Abu Dhabi launched the UAE's first clinical trial for the treatment of retinitis pigmentosa linked to the MerTK gene, using an innovative gene therapy developed by Opus Genetics, reflecting the emirate's commitment to advanced solutions for rare diseases. In another medical achievement, a specialised team at Corniche Hospital successfully diagnosed a rare case of partial anomalous pulmonary venous drainage (PAPVD) in a newborn at an early stage, improving treatment outcomes and preventing complications. Meanwhile, a medical team at Madinat Zayed Hospital in Al Dhafra successfully treated a complex renal condition using advanced interventional radiology techniques, demonstrating the efficiency of medical cadres and the continuous development of healthcare services across the emirate.